Immunome Inc Ordinary Shares IMNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
-
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
-
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
-
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
-
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
-
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $24.17
- Day Range
- $22.28–24.23
- 52-Week Range
- $7.96–27.65
- Bid/Ask
- $22.37 / $23.30
- Shares Outstanding
- 113.25M
- Market Cap
- $2.64B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 581.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 177
- Website
- https://www.immunome.com
Valuation
|
Metric
|
IMNM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.69 |
Price/Sales | 581.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMNM
|
|---|---|
Quick Ratio | 21.26 |
Current Ratio | 21.68 |
Interest Coverage | — |
Quick Ratio
IMNM
Profitability
|
Metric
|
IMNM
|
|---|---|
Return on Assets (Normalized) | −43.65% |
Return on Equity (Normalized) | −47.42% |
Return on Invested Capital (Normalized) | −50.36% |
Return on Assets
IMNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|z^^gwzB | LOCK|?$?< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|p>#!Vw | LOCK|$Qplv | $70B | |||
| argenx SE ADR
ARGX
| LOCK|lvmnYC | LOCK|$&$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Z?%&hnN | LOCK|^KN?^ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&p$B#&g | LOCK|^> | $36B | |||
| Moderna Inc
MRNA
| LOCK|Jdmj&< | LOCK|>$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<%$M@@p | LOCK|KS$q | $25B | |||
| Incyte Corp
INCY
| LOCK|^!K%%?N | LOCK|n$q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|hDMzw? | LOCK|#dc | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$$v^kx | LOCK|!d | $17B |
United States